%0 Journal Article
%T EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report
%A Chuang Qi
%A Peng Li
%A Tong Zhou
%A Xiaoyue Zhou
%A Yang Ling
%J SCIE-indexed Journal
%D 2018
%R 10.21037/jtd.2018.12.26
%X EGFR mutation is an important driving event in the development of non-small cell lung cancer (NSCLC), especially in pathologically diagnosed lung adenocarcinoma and non-smoking women in Asia (1). Compared with traditional platinum-containing chemotherapy, NSCLC patients with certain EGFR sensitive mutations showed higher clinical response to EGFR tyrosine kinase inhibitors (EGFR-TKIs), as confirmed by a series of phase III clinical trials, such as WJTOG3405, OPTIMAL, LUXLUNG6 and so on
%U http://jtd.amegroups.com/article/view/25921/html